8-K: Inspire Medical Systems Showcases Next-Generation Inspire V System at Wells Fargo MedTech Spotlight

Inspire Medical Systems, Inc. presented its latest advancements, including the new Inspire V system for obstructive sleep apnea, and strategic priorities at the Wells Fargo 2025 MedTech Innovation Spotlight.

Summary

• Inspire Medical Systems, Inc. filed a Form 8-K to announce its participation in various meetings with investors and analysts in June 2025, furnishing its presentation materials as an exhibit.
• The presentation highlights the Inspire V system, a next-generation closed-loop system for treating obstructive sleep apnea (OSA), which had its full launch in May 2025.
• Key features of Inspire V include an accelerometer-based respiration sensing technology, replacing the previous pressure sensor lead, which simplifies the implant procedure by eliminating one lead.
• The Inspire V system offers a 20% reduced implant time, improved therapy performance, and is designed to result in fewer revisions.
• The technology allows for stimulation of multiple targets, multiple sensing modes, and includes a flexible software platform for downloadable features, clinical studies, and future upgrades like posture-responsive therapy, auto start/pause, and AHI detection.
• The system boasts a consistent long battery life of 11 years on average and features SleepSync Connectivity for future remote programming and software updates.
• The company emphasizes its commitment to enhancing patient lives through sleep innovation, focusing on operational excellence, therapy adoption, and strengthening organizational culture.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook on the company's new product, Inspire V, emphasizing its technological advancements, patient benefits, and strategic importance. It is a promotional investor presentation with no negative disclosures.

Positives

• The Inspire V system offers a 20% reduction in implant time, making the procedure more efficient for patients and providers.
• Improved therapy performance and fewer revisions are expected with the new Inspire V system, enhancing patient outcomes.
• The accelerometer-based sensing in Inspire V simplifies the implant procedure by eliminating one lead, reducing complexity.
• The flexible software platform allows for future innovations, including downloadable features, posture-responsive therapy, auto start/pause, and AHI detection.
• The device has a long average battery life of 11 years, providing extended therapy without frequent replacements.
• SleepSync Connectivity enables future remote programming and software updates, offering convenience and adaptability.
• The company's core values emphasize patient-centricity, operational excellence, and driving therapy adoption, indicating a strong strategic focus.

Risks

• The Form 8-K includes a standard disclaimer that the information and presentation materials shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into other filings, except as expressly set forth by specific reference, indicating the forward-looking nature of some statements.

Future Outlook

The company anticipates future innovation through its flexible software platform, enabling downloadable features for clinical studies and field upgrades. Potential future features for Inspire V include posture-responsive therapy, auto start/pause, and AHI detection. SleepSync Connectivity is also expected to support future remote programming and software updates for all components.

Management Comments

• "With the release of Inspire 5, one of the most exciting new features is the change in how Inspires respiration sensing technology works. Inspire 5 has incorporated all our collective knowledge and experience about how to measure a patient's breathing pattern directly inside the generator using an accelerometer."
• "With this innovation, there is one less lead implanted in the body and the implant procedure is simplified."
• "Inspire is designed to turn on and off with the patient's breathing cycle to prevent tongue muscle fatigue."
• "Timing of stimulation is critical to target the most vulnerable portion of the breathing cycle to prevent airway collapse."
• "Inspire 5's new accelerometer-based sensing not only makes the implant easier, but it continues to deliver stimulation at the right time to ensure the best possible patient outcomes."

Industry Context

Inspire Medical Systems operates within the MedTech industry, specifically focusing on innovative solutions for obstructive sleep apnea (OSA). The introduction of the Inspire V system with accelerometer-based sensing represents an advancement in implantable neurostimulation devices for sleep apnea, aiming to provide a mask-free alternative to traditional treatments like CPAP.

Comparison to Industry Standards

• The company's approach is rooted in research, citing Dr. Alan Schwartz's 1996 work at Johns Hopkins, which proved rhythmic stimulation targeting the inhalation phase could stabilize OSA.
• The STAR trial verified the importance of turning on stimulation during the late exhalation phase for success.
• Research by Doctor Stefan and colleagues in 2019 highlighted the negative impact of poor stimulation timing on AHI, reinforcing the importance of Inspire's precise sensing algorithm.

Stakeholder Impact

• **Shareholders:** The introduction of an advanced product like Inspire V could positively impact future revenue and market share, potentially leading to increased shareholder value.
• **Patients:** Patients with obstructive sleep apnea stand to benefit from a simplified implant procedure, improved therapy performance, and potentially fewer revisions with the Inspire V system.
• **Healthcare Providers:** The reduced implant time and simplified procedure for Inspire V could make the treatment more appealing and efficient for medical professionals.
• **Employees:** Continued innovation and market leadership could foster a stable and growth-oriented environment for employees.

Next Steps

• Continued participation in various meetings with investors and analysts in June 2025.
• Potential future software updates and feature enhancements for the Inspire V system, including posture-responsive therapy, auto start/pause, and AHI detection.
• Ongoing remote programming and software updates for all components via SleepSync Connectivity.

Key Dates

Recommendation

Keywords

Inspire Medical Systems, INSP, Obstructive Sleep Apnea, OSA, Upper Airway Stimulation, UAS, Inspire V, Medical Device, MedTech, Accelerometer, Sleep Innovation, Implantable Device, SleepSync